Clinical trials: Constipation
Constipation
Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
The primary objective of the study was to evaluate the proportion of subjects with a bowel movement (BM) without straining or without hard and/or lumpy stool within the first 24 h of treatment for subjects taking 1 of 3 single…
- Trial name
- NCT01212445
- Testing
- PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
- Where
- Ireland
- Volunteers
- 154 people
- Sponsor
- Bayer
Functional Constipation
Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in…
- Trial name
- NCT01038687
- Testing
- A3309
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Michael Camilleri, MD
Anorexia Nervosa, Constipation
The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa
The aim of this study is to investigate whether Lactobacillus reuteri could have a beneficial role in treatment of children and adolescents with Anorexia nervosa who develop motility disorder due to the malnutrition regarding the…
- Trial name
- NCT02004288
- Testing
- Lactobacillus reuteri Protectis DSM17938
- Where
- Croatia
- Volunteers
- 31 people
- Sponsor
- BioGaia AB
Constipation
A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation
Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal.
- Trial name
- NCT00299975
- Testing
- MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose, MaZiRenWan (MZRW) High dose
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Hong Kong Baptist University
Opioid-Induced Constipation
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral MNTX for the treatment of opioid induced constipation in…
- Trial name
- NCT01186770
- Testing
- Methylnaltrexone
- Where
- 2 sites in United States
- Volunteers
- 804 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The objectives of this study are to evaluate the safety, efficacy, and dose response of two delayed release formulations of linaclotide (DR; DR formulation 1 is DR1; DR formulation 2 is DR2) administered orally to patients with…
- Trial name
- NCT02559206
- Testing
- Linaclotide
- Where
- 71 sites in United States
- Volunteers
- 759 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Opioid Induced Constipation (OIC)
A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)
Study (07-IN-NX003) is a Phase 2, multi-center, placebo-controlled, double-blind, randomized, dose-escalation trial. It is designed to investigate the safety, efficacy and tolerability of NKTR-118 (PEG-naloxol) in patients with…
- Trial name
- NCT00600119
- Testing
- NKTR-118
- Where
- 33 sites in United States
- Volunteers
- 207 people
- Sponsor
- AstraZeneca
Chronic Pain, Opioid Induced Constipation
Naloxone SR Capsules in Patients With Opioid Induced Constipation
For many patients taking opioids for pain relief one of the most distressing side effects is constipation. Naloxone is effective in the reversal of the effects of opioids and is used following opioid overdose.
- Trial name
- NCT00984334
- Testing
- Naloxone SR 5 mg capsules, Naloxone SR 10 mg capsules, Naloxone SR 20mg capsules
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- S.L.A. Pharma AG
Constipation
B. Lactis HN019 for Functional Constipation
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with functional constipation.
- Trial name
- CTT (NCT01463293)
- Testing
- B. lactis HN019
- Where
- 12 sites in United States
- Volunteers
- 224 people
- Sponsor
- Fonterra Research Centre
Constipation, Fecal Incontinence
Long Term Efficacy of Sacral Nerve Modulation (SNM) in Patients With Constipation or Stool Incontinence
The aim of this study is to determine the success rate, the success duration, the complication rate, maintenance effort and quality of life several years after sacral nerve modulation (SNM) treatment for constipation or stool…
- Trial name
- NCT02836717
- Testing
- sacral nerve modulation
- Volunteers
- 101 people
- Sponsor
- Cantonal Hospital of St. Gallen
Overactive Bladder, Constipation
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
Dysfunctional voiding is often associated with constipation. The association of constipation with urologic pathologic processes has previously been described since the 1950's, but it was only over the past decade that clinicians…
- Conditions
- Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
- Trial name
- NCT01003249
- Testing
- Baclofen
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Wake Forest University Health Sciences
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 2 (NCT00724126)
- Testing
- Rifaximin
- Where
- 88 sites in United States
- Volunteers
- 637 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid Induced Constipation
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
- Trial name
- NCT03060512
- Testing
- Polyethylene Glycol 3350, Movantik
- Where
- 53 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Constipation Predominant Irritable Bowel Syndrome
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria.
- Trial name
- T3MPO-3 (NCT02727751)
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Ardelyx
Neoplasms, Constipation
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.
- Conditions
- Neoplasms, Constipation, Opioid-Related Disorders
- Trial name
- NCT01004393
- Testing
- Methylnaltrexone bromide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Vermont
Back Pain, Low Back Pain
Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
This was a clinical effectiveness trial designed to compare the effectiveness, safety, and tolerability of treatment with tapentadol prolonged release with that of oxycodone/naloxone prolonged release in non-opioid pre-treated…
- Conditions
- Back Pain, Low Back Pain, Neuropathic Pain
- Trial name
- NCT01838616
- Testing
- Tapentadol Prolonged Release, Oxycodone/Naloxone Prolonged Release
- Where
- 50 sites in Austria, Germany and 2 more
- Volunteers
- 367 people
- Sponsor
- Grünenthal GmbH
Constipation
Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Patients with constipation often have bloating and abdominal distension. It is unclear if this is related to intestinal bacteria.
- Trial name
- NCT00844831
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Louisville
Colonic Motility Index, Constipation
Effect of Octreotide on the Colonic Motility in Pediatric Patients
The research study is designed to test how a medication called octreotide affects the motility (contraction or squeezing) of the colon (large intestine).
- Trial name
- NCT01917773
- Testing
- Octreotide, Bisacodyl
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Indiana University
Functional Constipation in Children Ages 6-17 Years
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years.
- Trial name
- NCT02559570
- Testing
- LIN Dose A, LIN Dose B, LIN Dose C
- Where
- 62 sites in United States, Canada
- Volunteers
- 173 people
- Sponsor
- Forest Laboratories
Constipation-predominant Irritable Bowel Syndrome
Cheno Effect on Transit in Health and IBS-C
The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
- Trial name
- Chenotransit (NCT00912301)
- Testing
- Sodium chenodeoxycholate (NaCDC)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic